A Phase 3 randomized, open-label trial of selinexor, pomalidomide, and dexamethasone versus elotuzumab, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma

被引：0
|
作者：
Weisel, Katja [1 ]
Bentur, Ohad [2 ]
Van Domelen, Dane [2 ]
Boccadoro, Mario [3 ]
Sonneveld, Pieter [4 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[2] Karyopharm, Newton, MA USA
[3] Cattedra Ematol, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy
[4] Erasmus MC Canc Inst, Rotterdam, Netherlands
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-323
引用
收藏
页码：S216 / S217
页数：2
相关论文
共 50 条
  • [1] CheckMate 602: A Phase 3, Open-Label, Randomized Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
    Lonial, Sagar
    Richardson, Paul
    Reece, Donna
    Mohamed, Hesham
    Shelat, Suresh
    San Miguel, Jesus
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S330 - S330
  • [2] CheckMate 602: An open-label, randomized, phase 3 trial of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
    Lonial, Sagar
    Richardson, Paul G.
    Reece, Donna Ellen
    Mohamed, Hesham
    Shelat, Suresh
    Miguel, Jesus San
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
    Chen, Christine I.
    Bahlis, Nizar
    Gasparetto, Cristina
    Tuchman, Sascha A.
    Lipe, Brea C.
    Baljevic, Muhamed
    Kotb, Rami
    Sutherland, Heather J.
    Bensinger, William I.
    Sebag, Michael
    Leblanc, Richard
    Venner, Christopher P.
    Schiller, Gary J.
    Lentzsch, Suzanne
    Callander, Natalie Scott
    Sheehan, Heidi
    Chai, Yi
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    White, Darrell J.
    BLOOD, 2019, 134
  • [4] LINKER-MM3, a phase 3, open-label, randomized study of linvoseltamab versus elotuzumab, pomalidomide, and dexamethasone (EPd) in relapsed/refractory multiple myeloma (RRMM)
    Weisel, Katja
    Hungria, Vania
    Quach, Hang
    Yoon, Sung-Soo
    Rodriguez-Otero, Paula
    Sinha, Arijit
    Boyapati, Anita
    Lyon, Charlotte
    Moore, Vygngley
    Inocencio, Tim
    Harnett, James
    Chi, Lei
    Lorenc, Karen Rodriguez
    Kroog, Glenn
    Voorhees, Peter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S63 - S64
  • [5] Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3trial
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Boccadoro, Mario
    Delimpasi, Sosana
    Beksac, Meral
    Katodritou, Eirini
    Moreau, Philippe
    Baldini, Luca
    Symeonidis, Argiris
    Bila, Jelena
    Oriol, Albert
    Mateos, Maria -Victoria
    Einsele, Hermann
    Orfanidis, Ioannis
    Kampfenkel, Tobias
    Liu, Weiping
    Wang, Jianping
    Kosh, Michele
    Tran, Namphuong
    Carson, Robin
    Sonneveld, Pieter
    LANCET HAEMATOLOGY, 2023, 10 (10): : E813 - E824
  • [6] Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Boccadoro, Mario
    Delimpasi, Sosana
    Beksac, Meral
    Katodritou, Eirini
    Moreau, Philippe
    Baldini, Luca
    Symeonidis, Argiris
    Bila, Jelena
    Oriol, Albert
    Mateos, Maria-Victoria
    Einsele, Hermann
    Orfanidis, Ioannis
    Ahmadi, Tahamtan
    Ukropec, Jon
    Kampfenkel, Tobias
    Schecter, Jordan M.
    Qiu, Yanping
    Amin, Himal
    Vermeulen, Jessica
    Carson, Robin
    Sonneveld, Pieter
    LANCET ONCOLOGY, 2021, 22 (06): : 801 - 812
  • [7] A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma.
    San Miguel, Jesus
    Raab, Marc S.
    Goldschmidt, Hartmut
    Lonial, Sagar
    Richardson, Paul G.
    Shelat, Suresh
    Bleickardt, Eric W.
    Palumbo, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Isatuximab, Pomalidomide, and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed / Multiple Myeloma Refractory (RRMM)
    Niederwieser, Dietger
    Richardson, Paul
    Attal, Michel
    Rajkumar, Vincent
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulosu, Meletios
    Huan, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Mace, Sandrine
    Prince, H. Miles
    Corzo, Kathryn P.
    Campana, Frank
    Le-Guennec, Solenn
    Dubin, Franck
    Anderson, Kenneth C.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 40 - 41
  • [9] Pomalidomide, bortezomib, and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma (OPTIMISMM): final survival outcomes from a randomized, open-label, phase 3 trial
    Beksac, Meral
    Richardson, Paul
    Oriol, Albert
    Lindsay, Jindriska
    Schjesvold, Fredrik
    Galli, Monica
    Yagci, Munci
    Larocca, Alessandra
    Weisel, Katja
    Yu, Xin
    Donahue, Cynthia
    Acosta, Jorge
    Peluso, Teresa
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S27 - S28
  • [10] Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
    Mateos, Maria-Victoria
    Blacklock, Hilary
    Schjesvold, Fredrik
    Oriol, Albert
    Simpson, David
    George, Anupkumar
    Goldschmidt, Hartmut
    Larocca, Alessandra
    Chanan-Khan, Asher
    Sherbenou, Daniel
    Avivi, Irit
    Benyamini, Noam
    Iida, Shinsuke
    Matsumoto, Morio
    Suzuki, Kenshi
    Ribrag, Vincent
    Usmani, Saad Z.
    Jagannath, Sundar
    Ocio, Enrique M.
    Rodriguez-Otero, Paula
    San Miguel, Jesus
    Kher, Uma
    Farooqui, Mohammed
    Liao, Jason
    Marinello, Patricia
    Lonial, Sagar
    LANCET HAEMATOLOGY, 2019, 6 (09): : E459 - E469
12345